Antibody levels after COVID-19 vaccination inversely linked to body weight
May 23, 2022
An inverse correlation was sustained for up to six months following two doses of BNT162b2 (Pfizer–BioNTech) in a small cohort of healthy young and middle-aged adults.
Adverse effects generally mild after BNT162b2 mRNA booster in over 60s
Apr 18, 2022
Thirty percent of those aged 60 years or older receiving a booster reported at least one adverse event; few sought medical attention.
Risk for myocarditis low after third dose of BNT162b2 vaccine
Mar 24, 2022
The incidence of myocarditis among young men estimated to be 6.43 and 11.25 per 100,000 vaccines in the week to two weeks after third dose..
Neutralization titers against omicron up with mRNA-1273 boost
Jan 28, 2022
After a mRNA-1273 (Moderna) boost, neutralization titers against the omicron variant were 20 times higher than than those at one month after second dose.
Thrombosis, thrombocytopenia syndrome up after Ad26.COV2.S
Jan 28, 2022
Rates of 3.83 per million vaccine doses for Ad26.COV2.S (Johnson & Johnson) have been reported, versus 0.00855 per million for mRNA-based vaccines such as Pfizer-BioNTech and Moderna.
mRNA COVID-19 vaccine less protective in elderly with comorbidity
Dec 23, 2021
At ≥7 days after the second dose, the effectiveness of mRNA COVID-19 vaccine was 69% against infection and 86% against related death.
COVID-19 certification mandates may increase vaccine uptake
Dec 22, 2021
Country-specific information, such as prior vaccination uptake and vaccine hesitancy, may influence the effect of COVID-19 certification mandates.
Myocarditis, myopericarditis risk up after SARS-CoV-2 vaccination
Dec 17, 2021
SARS-CoV-2 mRNA vaccination is associated with a significantly increased risk for myocarditis or myopericarditis for those receiving the mRNA-1273 (Moderna) vaccine and among females receiving the BNT162b2...
Immune response may vary with choice of COVID-19 booster
Dec 16, 2021
All seven vaccines tested boosted immunity following two doses of ChAdOx1 nCoV-19; six of seven did so following two doses of BNT162b2.
Moderna asks FDA to approve its booster shot for all adults
Nov 18, 2021
The Moderna booster is half the dose of the initial vaccination series: 50 mcg versus 100 mcg.